<DOC>
	<DOCNO>NCT00034879</DOCNO>
	<brief_summary>A program patient non small cell lung cancer may benefit Iressa , enter another clinical trial due eligible , trial available .</brief_summary>
	<brief_title>Iressa Expanded Access Program ( EAP )</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Inclusion Criteria For inclusion trial , patient must fulfill follow criterion : previous document histologically cytologically confirm nonsmall cell lung cancer ; locally advance and/or metastatic nonoperable nonsmall cell lung cancer ( stage III IV ) patient receive least one course standard systemic chemotherapy radiation therapy ineligible chemotherapy radiotherapy ineligible candidate enrollment another ZD1839 trial , Investigator 's opinion , medically suitable chemotherapy . age 18 year old ; write informed consent participate trial . Exclusion Criteria Any follow exclude patient enter trial : receiving concurrent radiotherapy , chemotherapy , systemic anticancer medication investigational agent . * Noncytotoxic hormonal therapy adjuvant treatment cancer previously treat cancer may allow per AstraZeneca permission ; patient eligible previously enrol ZD1839 blind clinical trial protocol . Patients eligible previously enrol openlabel unblinded ZD1839 clinical trial may consider acceptance Expanded Access Program AstraZeneca permission ; active malignancy ; incomplete heal previous oncologic major surgery ; evidence significant clinical disorder laboratory find make undesirable patient participate trial ; pregnancy breast feeding ( woman childbearing potential ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Locally advanced and/or metastatic non-operable</keyword>
	<keyword>non-small cell lung cancer ( stage III IV )</keyword>
	<keyword>patient fail standard therapy .</keyword>
</DOC>